MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jitc-2022-006570

Медицинская библиотека · Journal for immunotherapy of cancer · 2023

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.

Caulfield Jasmine I, Aizenbud Lilach, Perdigoto Ana Luisa, Meffre Eric, Jilaveanu Lucia, Michalek Dominika A, Rich Stephen S, Aizenbud Yariv, Adeniran Adebowale, Herold Kevan C, Austin Matthew R, Kluger Harriet

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

BACKGROUND

Immune checkpoint inhibitors (ICIs) have dramatically improved survival in patients with cancer but are often accompanied by severe immune-related adverse events (irAEs), which can sometimes be irreversible. Insulin-dependent diabetes is a rare, but life-altering irAE. Our purpose was to determine whether recurrent somatic or germline mutations are observed in patients who develop insulin-dependent diabetes as an irAE.

METHODS

We performed RNA and whole exome sequencing on tumors from 13 patients who developed diabetes due to ICI exposure (ICI-induced diabetes mellitus, ICI-DM) compared with control patients who did not develop diabetes.

RESULTS

In tumors from ICI-DM patients, we did not find differences in expression of conventional type 1 diabetes autoantigens, but we did observe significant overexpression of ORM1, PLG, and G6PC, all of which have been implicated in type 1 diabetes or are related to pancreas and islet cell function. Interestingly, we observed a missense mutation in NLRC5 in tumors of 9 of the 13 ICI-DM patients that was not observed in the control patients treated with the same drugs for the same cancers. Germline DNA from the ICI-DM patients was sequenced; all NLRC5 mutations were germline. The prevalence of NLRC5 germline variants was significantly greater than the general population (p=5.98×10-6). Although NLRC5 is implicated in development of type 1 diabetes, germline NLRC5 mutations were not found in public databases from patients with type 1 diabetes, suggesting a different mechanism of insulin-dependent diabetes in immunotherapy-treated patients with cancer.

CONCLUSIONS

Validation of the NLRC5 mutation as a potential predictive biomarker is warranted, as it might improve patient selection for treatment regimens. Furthermore, this genetic alteration suggests potential mechanisms of islet cell destruction in the setting of checkpoint inhibitor therapy.

Для цитирования: Caulfield Jasmine I, Aizenbud Lilach, Perdigoto Ana Luisa, Meffre Eric, Jilaveanu Lucia, Michalek Dominika A, Rich Stephen S, Aizenbud Yariv, Adeniran Adebowale, Herold Kevan C, Austin Matthew R, Kluger Harriet. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.. Journal for immunotherapy of cancer. 2023. DOI: 10.1136/jitc-2022-006570.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.